PRTK investment stock information. Paratek Pharmaceuticals Inc.
83 Millionen für das laufende Quartal berichtet Zacks Investment Research.
Paratek pharmaceuticals inc. Paratek Pharmaceuticals Inc. Ist ein biopharmazeutisches Unternehmen in der klinischen Phase. PRTK 744 down 016 -210 Related Articles.
Paratek Pharmaceuticals Inc. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. The Company is focused on the development and commercialization of.
Click here for webcast. Is a clinical-stage biopharmaceutical company. Dieser Wert wird als Zweitlisting im Freiverkehr gehandelt.
PRTK CEO Evan Loh on Q4 2020. 100920 2014aratek Pharmaceuticals to Present at HC. PRTK detailed stock quotes stock data Real-Time ECN charts stats and more.
Is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other. Paratek Pharmaceuticals PRTK Q4 2020 Earnings Call Transcript. Wall Street-Analysten sagen voraus dass Paratek Pharmaceuticals Inc.
Wainwright 22nd Annual Global Investment Conference Paratek Pharmaceuticals Inc. Its product candidates are the antibacterials omadacycline and sarecycline. Is a clinical-stage biopharmaceutical company.
Die Paratek Pharmaceuticals Inc Aktie wird unter der ISIN US6993743029 an den Börsen Frankfurt München Stuttgart Berlin NASDAQ Bats NDB Gettex Tradegate Lang. Ausführliches Aktienporträt der Paratek Pharmaceuticals - WKN A12EGE ISIN US6993743029 - bei finanztreffde topaktuell. The issuers publication requirements are in accordance with the regulations of the respective home market and may considerably fall behind those of the Regulated Market.
Get the latest Paratek Pharmaceuticals Inc. 16 Zeilen Paratek Pharmaceuticals Inc. Die höchste Umsatzschätzung liegt bei 36.
PARATEK PHARMACEUTICALS A12EGE US6993743029 mit aktuellem Aktienkurs Charts News und Analysen. NASDAQPRTK will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 17. Home Investors Events Presentations Paratek Pharmaceuticals Inc Q1 2021 Earnings Conference Call Event Details.
Die Publizitätspflichten des Emittenten richten sich nach den Bestimmungen des jeweiligen Heimatmarktes und können deutlich hinter denen des Regulierten Marktes zurückbleiben. NASDAQPRTK Q1 2021 Earnings Conference Call May 17 2021 0830 ET Company Participants Ben Strain - Vice President of Investor Relations Evan Loh - Chief. Paratek Pharmaceuticals Inc PRTK Q4 2018.
PRTK einen Umsatz von 543 ausweisen wird. Omadacycline is an antibiotic being developed for use as an empiric. Drei Analysten haben das Ergebnis von Paratek Pharmaceuticals geschätzt.
Das Unternehmen konzentriert sich auf die Entwicklung und Vermarktung von Therapeutika auf Basis der Tetracyclinchemie. Paratek Pharmaceuticals Inc Q1 2021 Earnings Conference Call. Millionen und der niedrigste ist 08.
NEW YORK NY ACCESSWIRE May 17 2021 Paratek Pharmaceuticals Inc. Monday May 17 2021 at 430 PM EDT Webcast Presentation. View Paratek Pharmaceuticals Inc.
This security is traded as a secondary listing on the Open Market. Die Produktkandidaten sind die.
Paratek Pharmaceuticals Prtk Receives A Buy From H C Wainwright Markets
Highest Paying Jobs At Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals Inc Stock Rating And Data Gurufocus Com
Paratek Pharmaceuticals Prtk Lifesci Capital
Jobs With Paratek Pharmaceuticals Inc
Gstaovmzqkxysm
Paratek Pharmaceuticals Inc Nasd Prtk Seasonal Chart Equity Clock
5 422 5 634 Paratek Pharmaceuticals Inc
Paratek Pharma Publications
Paratek Pharmaceuticals Abingworth Abingworth Llp
M4g7humkdfywwm
Paratek Pharmaceuticals Inc 2019 Current Report 8 K
Paratek Pharmaceuticals Crunchbase Company Profile Funding
5 422 5 634 Paratek Pharmaceuticals Inc
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.